Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-06 3:14 pm Purchase |
2025-02-10 | 13G | Odysight.ai Inc. ODYS |
Moshe Arkin | 7,926,329 41.900% |
7,926,329 (New Position) |
Filing History |
| 2024-08-26 10:01 am Purchase |
2024-08-19 | 13G | Eiger BioPharmaceuticals, Inc. EIGR |
Moshe Arkin | 149,371 10.090% |
96,300 (+181.46%) |
Filing History |
| 2024-07-01 06:47 am Sale |
2024-06-21 | 13D | Eiger BioPharmaceuticals, Inc. EIGR |
Moshe Arkin | 53,071 3.580% |
-96,300 (-64.47%) |
Filing History |
| 2024-04-08 09:28 am Purchase |
2024-04-19 | 13D | Sol-Gel Technologies Ltd. SLGL |
Moshe Arkin | 18,154,564 60.800% |
4,000,000 (+28.26%) |
Filing History |
| 2024-02-22 09:23 am Unchanged |
2023-07-28 | 13D | UroGen Pharma Ltd. URGN |
Moshe Arkin | 1,369,315 4.440% |
0 (Unchanged) |
Filing History |
| 2023-12-04 06:01 am Sale |
2023-11-14 | 13D | Eiger BioPharmaceuticals, Inc. EIGR |
Moshe Arkin | 149,371 10.090% |
-33 (-0.02%) |
Filing History |
| 2023-11-24 06:01 am Unchanged |
2023-11-14 | 13D | Eiger BioPharmaceuticals, Inc. EIGR |
Moshe Arkin | 149,404 10.090% |
0 (Unchanged) |
Filing History |
| 2023-04-18 09:59 am Purchase |
2023-04-10 | 13G | Eiger BioPharmaceuticals, Inc. EIGR |
Moshe Arkin | 149,404 10.150% |
58,971 (+65.21%) |
Filing History |
| 2023-03-20 4:45 pm Sale |
2023-01-27 | 13D | Sol-Gel Technologies Ltd. SLGL |
Moshe Arkin | 14,154,564 55.080% |
-363,702 (-2.51%) |
Filing History |
| 2023-02-02 2:25 pm Purchase |
2022-12-31 | 13G | Eiger BioPharmaceuticals, Inc. EIGR |
Moshe Arkin | 90,433 6.160% |
29,559 (+48.56%) |
Filing History |
| 2023-02-02 2:23 pm Sale |
2023-01-26 | 13G | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 1,371,074 4.980% |
-441,241 (-24.35%) |
Filing History |
| 2023-02-02 2:15 pm Purchase |
2022-12-31 | 13G | Oncorus, Inc. ONCR |
Moshe Arkin | 2,508,481 9.660% |
1,041,392 (+70.98%) |
Filing History |
| 2022-04-12 06:18 am Unchanged |
2022-04-11 | 13G | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 1,812,315 7.550% |
0 (Unchanged) |
Filing History |
| 2022-04-11 4:57 pm Sale |
2022-04-11 | 13G | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 1,812,315 7.550% |
-223,825 (-10.99%) |
Filing History |
| 2022-03-08 08:58 am Purchase |
2022-03-01 | 13G | Eiger BioPharmaceuticals, Inc. EIGR |
Moshe Arkin | 60,874 5.380% |
60,874 (New Position) |
Filing History |
| 2021-12-02 4:15 pm Purchase |
2021-11-22 | 13G | Oncorus, Inc. ONCR |
Moshe Arkin | 1,467,089 5.680% |
1,467,089 (New Position) |
Filing History |
| 2021-05-10 11:21 am Purchase |
2021-04-29 | 13D | Werewolf Therapeutics, Inc. HOWL |
Moshe Arkin | 2,046,634 7.400% |
2,046,634 (New Position) |
Filing History |
| 2020-12-17 06:48 am Unchanged |
2020-12-17 | 13D | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 2,036,140 8.790% |
0 (Unchanged) |
Filing History |
| 2020-11-25 06:31 am Unchanged |
2020-11-17 | 13D | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 2,036,140 8.790% |
0 (Unchanged) |
Filing History |